Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupat

Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single‐center experience

“…A possible explanation is that in atopic patients there is an alteration of the conjunctival tissue which appears to be more marked than in patients with other Th2 diseases 7 . Several hypotheses have been proposed for mechanisms driving conjunctivitis in dupilumab‐treated patients with AD, including alterations in cytokine activity leading to increased Demodex mites, increased of both levels of eosinophilic factors activation and activity of ligands (e.g., OX40 ligand), disruption of an immune‐mediated response of conjunctival‐associated lymphoid tissue, reduction of conjunctival goblet cells and mucin production induced by IL‐13 blocking effect of dupilumab 7‐9,13,14 …”

“…7 Several hypotheses have been proposed for mechanisms driving conjunctivitis in dupilumab-treated patients with AD, including alterations in cytokine activity leading to increased Demodex mites, increased of both levels of eosinophilic factors activation and activity of ligands (e.g., OX40 ligand), disruption of an immune-mediated response of conjunctival-associated lymphoid tissue, reduction of conjunctival goblet cells and mucin production induced by IL-13 blocking effect of dupilumab. [7][8][9]13,14 The International Eczema Council consensus guidelines recommend that a history of conjunctivitis or keratoconjunctivitis should not preclude dupilumab therapy. 15 As a prevention measure, it is advisable to suggest the use of artificial tears with hyaluronic acid to all the patients initiating treatment with dupilumab.…”

“…It is reported to be efficacious and safe for the treatment of moderate‐to‐severe AD, asthma, and chronic sinusitis 2–8 . Furthermore, in atopic patients the safety and efficacy of dupilumab has been proven in all ages, including adolescent from 12 years‐old and the elderly patients 5,9–11 . In May 2020, dupilumab was approved by the FDA in children 6–11 years of age with weight‐based dosing 12…”

“…[2][3][4][5][6][7][8] Furthermore, in atopic patients the safety and efficacy of dupilumab has been proven in all ages, including adolescent from 12 years-old and the elderly patients. 5,[9][10][11] In May 2020, dupilumab was approved by the FDA in children 6-11 years of age with weight-based dosing. 12 Dupilumab treatment in AD patients has been associated with ocular side effects such as conjunctivitis, blepharitis, keratitis, eye pruritus, and dry eye, from self-limiting mild forms up to rare severe cases requiring discontinuation of treatment.…”

Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study

“…Based on the experience acquired in adult patients and considering its proved efficacy and high safety profile, dupilumab can currently be considered for adolescents as a first-choice systemic treatment. 4 The treatment with dupilumab 200 or 300 mg every 2 weeks in adults and adolescents…”